Viatris ($VTRS) Insider Trading & Smart Money Activity

Viatris Inc. · Drug Manufacturers - Specialty & Generic · Latest filing Oct 5, 2026

Viatris Inc. ($VTRS) has 2 insider trades and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($1.62M), net -$1.62M.

Insider buyers (12 mo): 0
Insider sellers (12 mo): 1
Net insider $ (12 mo): -$1.62M
Congress trades (12 mo): 0
13F moves on file: 0
Analyst ratings on file: 2

VTRS insider buying and selling by quarter

Quarter	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0 / 0	0 / 0
Q2 2026	2 · $1.62M	0 / 0	0 / 0
Q3 2026	0	0 / 0	0 / 0
Q4 2026	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All VTRS insider, congress, 13F and analyst activity

Date	Source	Who	Action	Shares	Value / amount	1W	1M	Story
Oct 5, 2026	Analyst	UBS	Reiterates to Buy		PT $26	-0.5%		—
Sep 23, 2026	Analyst	Oppenheimer	Reiterates to Outperform		PT $25	+3.5%		—
Jun 25, 2026	Insider	Paul CampbellInterim Chief Financial Officer, Chief Accounting Officer and Corporate Controller	Sell (Open-market sale) 10b5-1	50.08K sh	$809.73K	+3.9%	+9.8%	Read
Jun 25, 2026	Insider	Paul CampbellInterim Chief Financial Officer, Chief Accounting Officer and Corporate Controller	Sell (Open-market sale) 10b5-1	50.08K sh	$809.73K	+3.9%	+9.8%	Read

1W / 1M / 6M = how VTRS moved from the trade or filing date.

Insider trading in VTRS: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
Paul Campbell	Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller	2	-$1.62M		Jun 25, 2026

Analyst ratings on VTRS

Date	Firm	Action	Rating	Price target	1W	1M	6M	Story
Oct 5, 2026	UBS	Reiterates	Buy	$23 → $26	-0.5%			—
Sep 23, 2026	Oppenheimer	Reiterates	Outperform	$25	+3.5%			—

Frequently asked questions

Are VTRS insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 2 open-market sales worth $1.62M, a net -$1.62M.

What is the latest insider trade in VTRS?

Paul Campbell, Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller filed a sell (open-market sale) of 50.08K sh worth $809.73K on Jun 25, 2026.

Other drug manufacturers - specialty & generic stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text